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Variations in the management of pneumonia in
pediatric emergency departments: compliance with
the guidelines
Aiman Alak, HBSc;* Jamie A. Seabrook, MA;† Michael J. Rieder, MD, PhD‡

ABSTRACT
Objective: We sought to assess compliance with evidencebased guidelines for the management of pediatric pneumonia, including the variations in tests ordered and antimicrobials prescribed. Our primary hypothesis was that compliance
with the treatment recommendations from the most current
guidelines would be low for antimicrobial prescriptions.
Methods: We conducted a chart review at the Children’s Hospital in London, Ont., to assess variation in the management
of pediatric pneumonia. All patients aged 3 months to 18 years
seen at the pediatric emergency department between Apr. 1,
2006, and Mar. 31, 2007, with a diagnosis of pneumonia were
eligible for inclusion in the study.
Results: Compliance with management guidelines was 59.7%
(95% confidence interval [CI] 53%–66%, n = 211) in children
5–18 years old and 83.0% (95% CI 80%–86%, n = 605) in children 3 months to 5 years old. Significant variation existed in
the choice of antimicrobial agent for children with pneumonia, with nonrecommended agents frequently prescribed.
Conclusion: Significant variation existed in the management of
pediatric pneumonia, and adherence to guidelines was low for
the group of patients aged 5–18 years. Future studies should
attempt to provide guidance to distinguish between viral and
bacterial etiology to allow judicious use of antimicrobials.
Keywords: pneumonia, child, pediatrics, disease management, physicians’ practice patterns

RÉSUMÉ
Objectif : Nous avons cherché à évaluer la conformité aux
lignes directrices fondées sur des données probantes pour la
prise en charge de la pneumonie chez les enfants, y compris
les variations dans les tests et les antimicrobiens prescrits.
Notre hypothèse principale était que le respect des recom-

mandations thérapeutiques des plus récentes lignes directrices était faible quant aux antimicrobiens prescrits.
Méthodes : Nous avons effectué un examen des dossiers à
l’Hôpital pour enfants de London, en Ontario, pour évaluer la
variation dans la prise en charge de la pneumonie chez les
enfants. Tous les patients âgés de 3 mois à 18 ans vus au
service des urgences pédiatriques entre le 1 avril 2006 et le
31 mars 2007 et ayant un diagnostic de pneumonie étaient
admissibles à l’étude.
Résultats : Le respect des lignes directrices était de 59,7 %
(intervalle de confiance [IC] à 95 %, de 53 à 66 %, n = 211)
chez les enfants de 5 à 18 ans et de 83,0 % (IC à 95 %, de 80 à
86 %, n = 605) chez les enfants de 3 mois à 5 ans. Des variations significatives existaient dans le choix d’un agent antimicrobien chez les enfants atteints de pneumonie, et des agents
non recommandés étaient fréquemment prescrits.
Conclusion : Des variations significatives existent dans la
prise en charge de la pneumonie chez les enfants, et le
respect des lignes directrices était faible pour le groupe de
patients âgés de 5 à 18 ans. Les études futures devraient
chercher à donner des conseils quant à la distinction entre les
étiologies virales et bactériennes pour permettre une utilisation judicieuse des antimicrobiens.

INTRODUCTION

In North America, the annual incidence of pneumonia
varies based on age group. For children younger than
5 years, the incidence is 30–45 per 1000 children; for
children aged 5–9 years, the incidence is 16–20 per
1000 children; for older children and adolescents, the
incidence is also 16–20 per 1000 children.1–4 Pneumonia can have devastating consequences. For example, in
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developing countries, sources estimate that pneumonia
causes 2 million childhood deaths annually.5 The difficulty of identifying the causative agents contributes to
the challenge of managing the treatment of pneu monia. Several research studies have shown that the
causative agent could not be identified in approximately half of cases.6–20 As determination of etiology is
difficult, empirical therapy is a common treatment
course.
Canadian guidelines for the treatment of pediatric
pneumonia approach the problem from an age-based,
etiologic perspective (Table 1).21 The consensus group
suggests therapy based on age group because of the association of age with particular causative agents. The
guidelines favour antibiotics with the narrowest spectral
range as well as ease of compliance. In terms of investigations, the guidelines make recommendations based on
consensus and the availability of tests, because no gold
standards exist for the determination of causative agents.
Useful diagnostic tests include chest radiography, complete and differential blood counts, blood cultures,
Gram staining and sputum culture, serologic testing for
Mycoplasma pneumoniae, culture and antigen detection of
viruses, a serologic test for viruses and a tuberculin skin
test. Conversely, throat cultures and antigen detection of
bacteria are not currently recommended. The extent to
which these guidelines are followed and the outcome
consequence of adherence to these guidelines for children with pneumonia is largely unknown. Kozyrskyj and
coworkers22 attempted to assess compliance with the
above guidelines; however, they used an overly stringent
interpretation of the guidelines.
Since the publication of these guidelines, trends that
might change treatment recommendations include the
use of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine and influenza vaccine.
Haemophilus influenzae type b vaccination was considered in the treatment guidelines and did not alter recommendations as the vaccine did not confer immunity
against nontypeable Haemophilus influenzae. Influenza

immunizations also have a small impact, as respiratory
viruses are still found in 15% of cases.21 Further, although the introduction of pneumococcal conjugate
vaccine likely decreased the frequency of pneumonia
due to Streptococcus pneumonia, this organism is still an
important cause of pneumonia in children.23,24
Management of treatment using best evidence and
guidelines will facilitate the delivery of high-quality
health care and may be both efficient and cost-effective.
Awareness of current diagnostic and management behaviour will assist in planning the modification of
behaviour to produce the highest quality of care at the
lowest possible cost. Judicious use of antibiotics will also
reduce the prevalence of pathogens with antimicrobial
resistance.25–27 In pursuit of this goal, we assessed variation in investigations, management and compliance
with guidelines in the treatment of pneumonia in children admitted to the emergency department (ED) at
the Children’s Hospital in London, Ont. Our primary
hypothesis was that compliance with treatment guidelines would be low for antimicrobial prescriptions. Our
secondary hypothesis was that compliance with investigations guidelines would be high.
METHODS

Patient charts from the Children’s Hospital were reviewed. The hospital is a publicly funded tertiary centre
affiliated with the University of Western Ontario and
uses a combination of electronic and paper-based medical records. The electronic system records tests that are
ordered and the test results, and medical notes and prescription orders are stored in the paper record.
The charts of patients aged 3 months to 18 years
seen at the pediatric ED between Apr. 1, 2006, and
Mar. 31, 2007, with a diagnosis of pneumonia (codes
480–487, 495.9, 507 from the clinical modification of
the International Classification of Disease, 9th revision [ICD-9-CM]) were considered eligible for inclusion in the study. Ethics approval was obtained from

Table 1. Summary of the Canadian guidelines for treatment of pediatric pneumonia*
Patient setting, recommendation
Patient age group
3 mo to 5 yr
5–18 yr

Outpatients

Patients in hospital

Amoxicillin or erythromycin or
clarithromycin
Erythromycin or clarithromycin

Cefuroxime or ampicillin
Erythromycin or clarithromycin (with
or without cefuroxime) or ampicillin

Patients in the intensive care unit
Cefuroxime plus (clarithromycin or
erythromycin)
Cefuroxime plus (clarithromycin or
erythromycin)

*Adapted from Jadavji et al.21
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the institutional review board at the University of
Western Ontario.
The patient’s age group (3 mo to 5 yr or 5–18 yr),
investigations, antibiotic treatment and route of administration were abstracted from the chart onto a data collection sheet by a reviewer who was unaware of the
study’s hypothesis. Each investigation was counted
once, even if a patient received the same test multiple
times. Admission to hospital and recent doctor visits
were also recorded. The number of patients with a positive laboratory culture test was noted.
Management
Treatment was considered compliant with management
guidelines if the following criteria were met:
• outpatients 3 months to 5 years old were treated with
amoxicillin, erythromycin or clarithromycin
• inpatients 3 months to 5 years old were treated with
at least cefuroxime or ampicillin
• outpatients 5–18 years old were treated with erythromycin or clarithromycin
• inpatients 5–18 years old were treated with at least
erythromycin, clarithromycin or ampicillin
In a subgroup analysis, antimicrobials from the same
class were considered suitable substitutes. For example,
azithromycin was considered equivalent to erythromycin and clarithromycin, cefprozil was considered a sufficient substitute for cefuroxime, and Clavulin was a sufficient substitute for amoxicillin.
Statistical analysis was completed using SPSS, version 15.0. Continuous variables were reported as means

with standard deviation. Categorical variables were
described as percentages with 95% confidence intervals.
The χ2 test or Fisher exact test was used to compare
proportions between groups. A 2-tailed probability of
p < 0.05 was used to establish statistical significance.
RESULTS

Chart review
A total of 816 children were seen in the pediatric ED
for pneumonia between Apr. 1, 2006, and Mar. 31,
2007. Of these, 605 patients were aged 3 months to
5 years and 211 patients were aged 5–18 years. In the
younger age group, 71 patients (11.7%) were admitted
to hospital, and 30 children (14.2%) in the older age
group were admitted.
Investigations
The investigations ordered are shown in Table 2. The
vast majority of these tests would be considered useful
by the guidelines criteria.21 Chest radiography was performed during almost all patient visits, with every 1 in
5 patients also undergoing complete and differential
blood counts. The most common culture test ordered
was a blood culture. Viral and throat cultures were used
to a lesser extent. In the younger age group, 12.1%
(15/124) of patients who had cultures ordered yielded
positive results compared with 7.3% (4/55) among
patients aged 5–18 years. Most of the positive cultures
(10/19) were for respiratory syncytial virus.
Compliance with treatment recommendations

Table 2. Investigations ordered in 816 children seen in the
pediatric emergency department for pneumonia
Age group, no. (%)
Investigation
Chest radiograph†
Complete and differential
blood counts†
Blood culture†
Viral culture†
Throat culture†
Other†‡
Positive culture in patients
who had cultures ordered

3 mo to 5 yr,
n = 605*
590 (97.5)
105 (17.4)
84
24
12
13
15/124

(13.9)
(4.0)
(2.0)
(2.1)
(12.1)

5–18 yr,
n = 211*
204 (96.7)
49 (23.2)
36
10
9
4
4/55

(17.1)
(4.7)
(4.3)
(2.0)
(7.3)

*Unless otherwise stated.
†p > 0.05 for a difference in test use between age groups.
‡Other tests include polymerase chain reaction for pertussis, fluid culture, serology
and fungal/yeast culture.
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Compliance with management guidelines was 59.7%
(126/211) in children 5–18 years old and 83.0%
(502/605) in children 3 months to 5 years old (p < 0.001)
(Table 3).21 Almost all outpatients received antibiotics
Table 3. Compliance with management guidelines in the
treatment of pneumonia in 816 children
No. (%) [95% confidence interval]
Age group
3 mo to 5 yr,
n = 605
5–18 yr,
n = 211

Adjusted compliance*

502 (83.0) [80%–86%] 599 (99.0) [98%–99%]
126 (59.7) [53%–66%] 144 (68.2) [62%–74%]

*Calculations based on a reinterpretation of the guidelines that equated antimicrobial
agents from the same drug class.
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orally, and almost all patients admitted to hospital received antibiotics intravenously. If the interpretation of
the guidelines was expanded to accept antimicrobials
from the same drug class, the differences between age
groups were even more pronounced. In this subgroup
analysis, compliance with guidelines was 99.0% (599/605)
in the care of children 3 months to 5 years old, and it was
68.2% (144/211) in the care of children 5–18 years old
(Table 3).
Significant variation existed in the choice of antimicrobial agent for children with pneumonia (Table 4).
Other than the recommended agents, children in the
age group 5–18 years also received amoxicillin (8.5% of
visits), azithromycin (8.5% of visits), Clavulin (5.7% of
visits), cefprozil (4.7% of visits) and clindamycin (1.9%
of visits). Other than the recommended agents, children
in the age group 3 months to 5 years also received
cefprozil (6.9% of visits), Clavulin (4.5% of visits),
azithromycin (3.5% of visits), cefotaxime (1.0% of visits) and ceftriaxone (1.0% of visits).
DISCUSSION

Despite the existence of accepted guidelines, we found
considerable variation in the management of pediatric
pneumonia by physicians in this Canadian pediatric ED.
Although the guidelines were published in 1997, they
remain the most current guidelines for the management
of pediatric pneumonia. For children 5–18 years old,
physician compliance with management guidelines was
Table 4. Choice of antimicrobial therapy in the treatment of
pneumonia in 816 children
Age group, no. (%)
Antimicrobial agent or route*
Amoxicillin
Clarithromycin
Cefuroxime
Cefprozil
Clavulin
Azithromycin
Cefotaxime
Ceftriaxone
Clindamycin
Other agents†
Oral route
Intravenous route

3 mo to 5 yr,
n = 605
337
134
45
42
27
21
6
6
2
10
593
59

(55.7)
(22.0)
(7.4)
(6.9)
(4.5)
(3.5)
(1.0)
(1.0)
(0.3)
(1.6)
(98.0)
(9.8)

5–18 yr,
n = 211
18 (8.5)
126 (60.0)
26 (12.3)
10 (4.7)
12 (5.7)
18 (8.5)
3 (1.4)
0 (0.0)
4 (1.9)
12 (5.7)
208 (98.6)
29 (13.7)

*Note that some children received more than 1 antimicrobial agent.
†Other agents include ceftazidime, cephalexin, ciprofloxacin, cloxacillin, erythromycin,
meropenem, tobramycin and vancomycin.

59.7%, and in younger children it was 83.0%.21 In the
subgroup analysis using drug classes instead of specific
agents, the compliance with guidelines was 99.0% in the
younger children and 68.2% in the older group of children. Almost all outpatients received antibiotics orally,
and almost all admitted patients received antibiotics
intravenously. In terms of variation from guidelines, this
was primarily related to the fact that a variety of nonrecommended agents were prescribed. Children in the
age group 5–18 years frequently received amoxicillin,
azithromycin, cefprozil, Clavulin and clindamycin.
Younger children commonly received azithromycin,
cefotaxime, cefprozil, ceftriaxone and Clavulin.
The significant majority of investigations ordered
were consistent with guideline recommendations.21
Chest radiography was used for almost all patient visits,
as radiography is the gold standard for the diagnosis of
pneumonia; however, a “clinical” diagnosis (e.g., no
chest radiograph) of pneumonia still occurred in this
academic centre.28 Other commonly ordered tests were
complete and differential blood counts and blood culture. Viral and throat cultures were used to a lesser
extent. Only the use of throat cultures would be considered noncompliant with the guidelines.21 Notably, however, the extent to which these investigations changed
management was limited. For example, cultures yielded
positive results in 7.3% and 12.1% of patients in the
older and younger age groups, respectively, mostly for
viral cultures. However, this did not change the management, as 98% of all patients received antimicrobial
agents. Possible explanations include the delays in
obtaining viral cultures or the clinicians’ suspicion of
mixed bacterial and viral infections.14
Interestingly, physicians were much more compliant
with the guidelines for younger compared with older
patients. The reasons for this are not clear. Known barriers to implementation of guidelines include parents
and physicians having issues with the efficiency of recommended therapies, fear of legal action,29 perceived
lack of flexibility of guidelines and lack of agreement
with the guidelines.30 Given the considerable experience
with the agents recommended in young children, it is
possible that the guidelines for younger children
inspired more confidence than those for older children.
Our findings likely represent an overestimate of
guideline adherence, as we did not consider dosing or
treatment durations. In addition, the physicians involved
in care were all board-certified pediatric emergency specialists at one academic centre, and, thus, adherence to
guidelines might not be representative of other centres
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or other physicians. Kozyrskyj and coworkers22 also
looked at evidence-based prescribing of antibiotics for
children. They used a narrow definition of noncompliance (prescription of any drug other than amoxicillin or
erythromycin for a child with pneumonia was considered non–evidence based), even though they were also
using the same Canadian guidelines. The authors also
did not make any distinction based on age groups. These
points make their results difficult to interpret.
Limitations
Our study has several limitations. First, we used a retrospective chart review to assess compliance with guidelines; however, the nature of the medical record system
at the Children’s Hospital eliminated incomplete data.
As mentioned, investigations and results were tabulated
electronically, and prescription notes were photocopied.
Second, we did not exclude patients with comorbidities
from our study population, whereas the guidelines
attempted to deal with otherwise healthy children;21
however, many children with pneumonia have comorbidities. Eliminating this subpopulation would reduce
the population of patients drastically and limit generalizability. It should be noted that guidelines for children
with pneumonia and other health issues do not currently exist. Third, our physician population consisted
of pediatric emergency specialists at one centre, which
might not be representative of the general physician
population or physicians at other centres.
CONCLUSION

This study assessed the variation in management and
compliance with guidelines in the treatment of pediatric
pneumonia in a Canadian ED. Whereas the vast majority of investigations ordered were consistent with guidelines recommendations, we also found that significant
heterogeneity existed in the types of antimicrobials prescribed for pediatric pneumonia. For antimicrobials,
compliance with guidelines was much lower for patients
5–18 years old; however, the reasons for this were not
clear. Further studies need to examine reasons for this
discrepancy and whether adherence to guidelines actually improves clinical outcome. Our findings suggest
that clinicians should be aware of the limited utility of
many of the tests ordered and be more judicious in
antimicrobial use. Future research could attempt to
identify better methods at establishing etiology, especially distinguishing between bacterial and viral pneu518
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monia. This latter distinction could markedly reduce
the prescription of antibiotics for pneumonia and
decrease the prevalence of microbes with antibiotic
resistance. Guidelines are needed for the therapy of
children with pneumonia with other comorbid conditions. Finally, cost-effectiveness studies of pediatric
pneumonia management are needed, particularly
exploring the utility and costs of investigations.
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